Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2)
Bioorganic & Medicinal Chemistry Letters · 2024
DOI: 10.1016/j.bmcl.2023.129558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2024. Verfasst von Xin Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China. Electronic address: xuxin@huahaipharm.com. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
The enhancer of zeste homolog 2 (EZH2) plays the role of the main catalytic subunit of polycomb repressive complex 2 (PRC2) that catalyzes the methylation of histone H3 lysine 27 (H3K27). Overexpression or mutation of EZH2 has been observed in many types of hematologic malignancies and solid tumors, such as myeloma, lymphoma, prostate, breast, kidney, and lung cancers. EZH2 has been demonstrated as a promising therapeutic target for the treatment of tumors. Based on the structure of 1 (EPZ-6438), a series of novel conformationally constrained derivatives were designed and synthesized aiming to improve the EZH2 inhibition activity, especially for mutated EZH2. Structure and activity relationship (SAR) exploration and optimization at both enzymatic and cellular levels led to the discovery of 28. In vitro, 28 displayed potent EZH2 inhibition activity with an IC50 value of 0.95 nM, which is comparable to EPZ-6438 (1). 28 exhibited high anti-proliferation activity against different lymphoma cell lines including WSU-DLCL2, Pfeiffer and Karpas-422 (IC50 = 2.36, 1.73, and 1.82 nM, respectively). In vivo, 28 showed acceptable pharmacokinetic characteristics (oral bioavailability F = 36.9%) and better efficacy than 1 in both Pfeiffer and Karpas-422 xenograft mouse models, suggesting that it can be further developed as a potential therapeutic candidate for EZH2-associated cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China. Electronic address: xuxin@huahaipharm.com.
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd., Shanghai, China.
Zitieren
APA
Xu, X., Chen, J., Wang, G., Zhang, X., Li, Q., Zhou, X., Guo, F., & Li, M. (2024). Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2). Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2023.129558
Vancouver
Xu X, Chen J, Wang G, Zhang X, Li Q, Zhou X, et al. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2). Bioorganic & Medicinal Chemistry Letters. 2024. doi:10.1016/j.bmcl.2023.129558
BibTeX
@article{Xu2024,
author = {Xu, Xin and Chen, Jia and Wang, Guan and Zhang, Xiaojuan and Li, Qiang and Zhou, Xiaobo and Guo, Fengying and Li, Min},
title = {Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2)},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2024},
doi = {10.1016/j.bmcl.2023.129558}
}
EUVIMED